Both cardiac and non-cardiac comorbidities tied to adverse outcomes in atrial fibrillation: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-11-01 03:30 GMT   |   Update On 2021-11-01 03:30 GMT
Advertisement

UK: In a recent study in the journal BMC Medicine, the researchers identified three main clusters in European atrial fibrillation (AF) patients. The clusters were -- older patients with non-cardiac comorbidities, older patients with cardiac comorbidities, and a younger, low-risk group. Both cardiac and non-cardiac comorbidities were associated with a greater risk of adverse outcomes.

Atrial fibrillation is a cardiovascular condition which has a multifactorial origin, with the involvement of several cardiovascular (CV) and non-CV risk factors and comorbidities contributing significantly to the development of incident AF. Epidemiological studies in AF show that clinical complexity increase the risk of major adverse outcomes. Marco Proietti, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK, and colleagues aimed to describe European AF patients' clinical phenotypes and analyse the differential clinical course.

Advertisement

For this purpose, the researchers performed a hierarchical cluster analysis based on Ward's Method and Squared Euclidean Distance using 22 clinical binary variables, identifying the optimal number of clusters. They also investigated differences in nvestigated differences in clinical management, use of healthcare resources and outcomes in a cohort of European AF patients from a Europe-wide observational registry. A total of 9363 were available for this analysis. 

The study revealed the following findings:

  • Three clusters were identified: Cluster 1 (n = 3634; 38.8%) characterized by older patients and prevalent non-cardiac comorbidities; Cluster 2 (n = 2774; 29.6%) characterized by younger patients with low prevalence of comorbidities; Cluster 3 (n = 2955;31.6%) characterized by patients' prevalent cardiovascular risk factors/comorbidities.
  • Over a mean follow-up of 22.5 months, Cluster 3 had the highest rate of cardiovascular events, all-cause death, and the composite outcome (combining the previous two) compared to Cluster 1 and Cluster 2.
  • An adjusted Cox regression showed that compared to Cluster 2, Cluster 3 (hazard ratio (HR) 2.87; HR 3.42; HR 2.79, and Cluster 1 (HR 1.88; HR 2.50; HR 2.09) reported a higher risk for the three outcomes respectively.

"In our study of European AF patients, we identified three main clusters, differentiated by differential presence of comorbidities," wrote the authors. "Both non-cardiac and cardiac comorbidities clusters were found to be associated with an increased risk of major adverse outcomes."

Reference:

Proietti, M., Vitolo, M., Harrison, S.L. et al. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Med 19, 256 (2021). https://doi.org/10.1186/s12916-021-02120-3


Tags:    
Article Source : BMC Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News